GenSight Biologics

105 articles about GenSight Biologics

• GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France

  7/5/2021

  GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the French Competent Authority, the National Agency for Medicines and Health Products Safety, granted a Cohort Temporary Authorization for Use for LUMEVOQ® in the treatment of Leber Hereditary Optic Neuropathy caused by a mutated ND4 gene.

• GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment

  6/30/2021

  GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported key efficacy and safety findings at 1.5 years post-treatment in the REFLECT Phase III clinical trial for LUMEVOQ®.

• GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering

  6/10/2021

  GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the appointment of Marion Ghibaudo as Chief Technical Officer.

• GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology

  6/1/2021

  GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ ® versus Natural History in Frontiers in Neurology Clinically meaningful difference between visual outcomes of LUMEVOQ ® -treated patients and untreated patients

• GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment

  5/31/2021

  GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will host a Key Opinion Leader call on June 4, 2021 from 8:00 am to 9:00 am EDT.

• 

  Gene Therapy Continues Edging into the Mainstream

  5/25/2021

  Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.

• GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch

  5/19/2021

  GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the Company’s country leads for three key European markets are in place.

• GenSight Biologics Appoints Françoise de Craecker to its Board of Directors

  5/17/2021

  GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the appointment of Françoise de Craecker to its Board of Directors, replacing Natalie Mount.

• 

  Clinical Catch-Up: May 3-7

  5/10/2021

  It was a busy week for clinical trial news. Here’s a look.

• GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye

  5/3/2021

  GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye Confirms that untreated ND4 LHON patients have the worst visual outcomes The natural history of ND4 LHON disease is characterized by severe and permanent deterioration of BCVA

• GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update

  4/20/2021

  GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported its cash position as of March 31, 2021, and provided an operational update.

• GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

  3/10/2021

  GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported its full year 2020 financial results and provided an outlook on 2021.

• GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs

  2/15/2021

  Early demonstration of favorable LUMEVOQ® safety profile in human subjects subsequently confirmed in later trials

• GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates

  2/4/2021

  First publication to document high spatiotemporal resolution and pattern discrimination by retinal ganglion cells expressing ChrimsonR‑tdT in non-human primates

• GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

  1/19/2021

  GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported its cash position as of December 31, 2020, and provided an operational update.

• GenSight Biologics Announces its 2021 Financial Calendar

  1/18/2021

  GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2021.

• GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

  1/13/2021

  GenSight Biologics announced that the journal of the American Academy of Ophthalmology, Ophthalmology®, has published results from the RESCUE pivotal Phase III clinical trial of LUMEVOQ® gene therapy in ND4 Leber Hereditary Optic Neuropathy subjects.

• GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine

  12/10/2020

  First publication based on Phase III data to document sustained and clinically meaningful bilateral improvement in visual acuity from unilateral injection of a gene therapy

• GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital

  12/10/2020

  Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the " Company " or " GenSight "), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today that it has received, in connection with its bond agreement entered with Kreos Capital VI (Expert Fund) LP

• Diamond Pharma Services Supports GenSight Biologics in Submitting Its First Marketing Authorisation Application, for Ocular Gene Therapy LUMEVOQ

  10/5/2020

  Diamond Pharma Services has provided EU regulatory, pharmacovigilance, quality and compliance support to GenSight, leading to the Marketing Authorisation Application for LUMEVOQ